Company profile: Deka Biosciences
1.1 - Company Overview
Company description
- Provider of cytokine therapy platforms, including Diakine™ combining cytokines in a single treatment for cancer and inflammatory diseases; an oncology platform with disease-targeting scaffolds that link cytokines to stimulate the immune system; an anti-inflammatory platform targeting specific tissue markers; precision medicine using genetic tests to personalize Diakines™; and manufacturing via a unique scaffold for higher yields and lower costs.
Products and services
- Anti-Inflammatory Platform: Combines anti-inflammatory cytokines targeted to specific tissue markers for treating inflammatory diseases, directing therapeutic activity to defined tissues (targeted)
- Diakine™ Platform: Combines cytokines in a single treatment to target the immune system for treating cancer and inflammatory diseases, unifying multi-cytokine therapy in one administration (modular)
- Oncology Platform: Employs disease-targeting scaffolds that link cytokines to stimulate the immune system against cancer cells, integrating scaffold-based cytokine assemblies for cancer-directed immune activation (custom-engineered)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Deka Biosciences
Rigel Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule drugs for autoimmune, cancer and metabolic diseases, offering REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation and TAVALISSE (fostamatinib) for adult chronic ITP; pipeline includes R289 for LR-MDS, milademetan (MDM2) for liposarcoma with Daiichi Sankyo, bemcentinib (AXL) for NSCLC with BerGenBio, and R552 (RIPK1) for rheumatoid arthritis with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rigel Pharmaceuticals company profile →
Serimmune
HQ: United States
Website
- Description: Provider of antibody repertoire profiling and immune analytics via the Serum Epitope Repertoire Analysis (SERA) platform to identify disease-specific antigens and epitopes in a single assay; immune profiling with high-resolution epitope mapping and immune status reports; biomarker discovery across infectious diseases, cancer, and autoimmunity; Titan panel covering 50+ infectious diseases; and population serosurveillance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serimmune company profile →
Allergy Therapeutics
HQ: United Kingdom
Website
- Description: Provider of European-based speciality pharmaceutical expertise focused on the treatment and prevention of allergy, offering general information for allergy sufferers and healthcare professionals on prevention, diagnosis and treatment, with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allergy Therapeutics company profile →
Abintus Bio
HQ: United States
Website
- Description: Provider of in vivo immune cell reprogramming solutions, offering programs for highly selective gene expression targeting—using synthetic biology to target specific cell types or states across gene delivery systems—for applications in leukemia, solid tumors, autoimmune, infectious, and genetic diseases, and simultaneous engineering of innate and adaptive immune cells for lymphoma and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abintus Bio company profile →
Apitope
HQ: United Kingdom
Website
- Description: Provider of discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis; first product candidate licensed to Merck Serono.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apitope company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Deka Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Deka Biosciences
2.2 - Growth funds investing in similar companies to Deka Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Deka Biosciences
4.2 - Public trading comparable groups for Deka Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →